These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33055121)
1. Industry ties and evidence in public comments on the FDA framework for modifications to artificial intelligence/machine learning-based medical devices: a cross sectional study. Smith JA; Abhari RE; Hussain Z; Heneghan C; Collins GS; Carr AJ BMJ Open; 2020 Oct; 10(10):e039969. PubMed ID: 33055121 [TBL] [Abstract][Full Text] [Related]
2. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. Moynihan R; Lai A; Jarvis H; Duggan G; Goodrick S; Beller E; Bero L BMJ Open; 2019 Feb; 9(2):e025864. PubMed ID: 30813119 [TBL] [Abstract][Full Text] [Related]
3. Mapping conflict of interests: scoping review. Chimonas S; Mamoor M; Zimbalist SA; Barrow B; Bach PB; Korenstein D BMJ; 2021 Nov; 375():e066576. PubMed ID: 34732464 [TBL] [Abstract][Full Text] [Related]
4. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Forsyth SR; Odierna DH; Krauth D; Bero LA Syst Rev; 2014 Nov; 3():122. PubMed ID: 25417178 [TBL] [Abstract][Full Text] [Related]
5. Financial disclosures of scientific papers presented at the 2003 RSNA Annual Meeting: association with reporting of non-Food and Drug Administration-approved uses of industry products. Brown SD; Daly JC; Kalish LA; McDaniel SA Radiology; 2006 Jun; 239(3):849-55. PubMed ID: 16641343 [TBL] [Abstract][Full Text] [Related]
6. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079 [TBL] [Abstract][Full Text] [Related]
7. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. Wang AT; McCoy CP; Murad MH; Montori VM BMJ; 2010 Mar; 340():c1344. PubMed ID: 20299696 [TBL] [Abstract][Full Text] [Related]
8. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. Moynihan R; Albarqouni L; Nangla C; Dunn AG; Lexchin J; Bero L BMJ; 2020 May; 369():m1505. PubMed ID: 32461201 [TBL] [Abstract][Full Text] [Related]
9. Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. Miller SL; Haslam A; Prasad V Eur J Clin Invest; 2024 Jun; 54(6):e14184. PubMed ID: 38407501 [TBL] [Abstract][Full Text] [Related]
10. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
11. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations. Boesen K; Gøtzsche PC; Ioannidis JPA Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608 [TBL] [Abstract][Full Text] [Related]
12. Marketing and US Food and Drug Administration Clearance of Artificial Intelligence and Machine Learning Enabled Software in and as Medical Devices: A Systematic Review. Clark P; Kim J; Aphinyanaphongs Y JAMA Netw Open; 2023 Jul; 6(7):e2321792. PubMed ID: 37405771 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations. Li DG; Singer S; Mostaghimi A JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625 [TBL] [Abstract][Full Text] [Related]
14. The 2021 landscape of FDA-approved artificial intelligence/machine learning-enabled medical devices: An analysis of the characteristics and intended use. Zhu S; Gilbert M; Chetty I; Siddiqui F Int J Med Inform; 2022 Sep; 165():104828. PubMed ID: 35780651 [TBL] [Abstract][Full Text] [Related]
15. Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. Fabbri A; Nejstgaard CH; Grundy Q; Bero L; Dunn AG; Mohammad A; Mintzes B J Gen Intern Med; 2022 Feb; 37(2):290-297. PubMed ID: 34037923 [TBL] [Abstract][Full Text] [Related]
16. Improving the use of research evidence in guideline development: 4. Managing conflicts of interests. Boyd EA; Bero LA Health Res Policy Syst; 2006 Dec; 4():16. PubMed ID: 17140441 [TBL] [Abstract][Full Text] [Related]
17. Disclosure of Financial Conflicts of Interest in Plastic and Reconstructive Surgery. Luce EA; Jackman CA Plast Reconstr Surg; 2017 Sep; 140(3):635-639. PubMed ID: 28841626 [TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
19. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. Lurie P; Almeida CM; Stine N; Stine AR; Wolfe SM JAMA; 2006 Apr; 295(16):1921-8. PubMed ID: 16639051 [TBL] [Abstract][Full Text] [Related]
20. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. Turner K; Carboni-Jiménez A; Benea C; Elder K; Levis B; Boruff J; Roseman M; Bero L; Lexchin J; Turner EH; Benedetti A; Thombs BD BMJ Open; 2020 May; 10(5):e035633. PubMed ID: 32398334 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]